Table 3 Interaction between smoking and polymorphisms involved in dopaminergic neurotransmission in Parkinson's disease
Polymorphism | Genotype | Non-smokers | Ever smokers | P inteaction | ||
|---|---|---|---|---|---|---|
| Â | Â | Cases/controls | Adjusted OR* (95% CI) | Cases/controls | Adjusted OR* (95% CI) | Â |
COMT | No risk†(GG) | 77/103 | 3.70 (1.95 - 7.02) | 21/76 | 1.0 (reference) | 0.061 |
rs4680 | At-risk†(GA + AA) | 97/119 | 3.97 (2.13 - 7.41) | 43/71 | 2.19 (1.17 - 4.10) |  |
MAOB | No risk‡ [GG (G) + AG] | 40/70 | 3.68 (1.30 - 10.4) | 6/26 | 1.0 (reference) | 0.434 |
rs1799836 | At- risk‡ [AA (A)] | 134/152 | 5.74 (2.16 - 15.2) | 58/121 | 2.39 (0.91 - 6.27) |  |
DRD2 | No risk‡ (TC + TT) | 108/153 | 2.32 (1.34 - 3.99) | 38/91 | 1.0 (reference) |  |
rs1800497 | At- risk‡ (CC) | 66/69 | 3.16 (1.75 - 5.70) | 26/56 | 1.12 (0.61 - 2.08) | 0.608 |
DRD4 | No risk†(CC) | 25/37 | 2.98 (1.18 - 7.56) | 10/33 | 1.0 (reference) |  |
rs1800955** | At- risk†(TT + TC) | 149/184 | 3.50 (1.57 - 7.80) | 54/114 | 1.48 (0.67 - 3.28) | 0.637 |